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Abstract: 
Abstract  
Objective: To develop a core outcome set (COS) applicable for 
effectiveness trials of all interventions for localised prostate cancer.  
Background: Many treatments exist for localised prostate cancer, 
although it is unclear which offers the optimal therapeutic ratio. This is 
confounded by inconsistencies in the selection, definition, measurement 
and reporting of outcomes in clinical trials.  
Subjects and methods: A list of 79 outcomes was derived from a 
systematic review of published localised prostate cancer effectiveness 
studies and semi-structured interviews with 15 prostate cancer patients. A 
two-stage consensus process involving 118 patients and 56 international 
healthcare professionals (HCPs) (cancer specialist nurses, urological 
surgeons and oncologists) was undertaken, consisting of a three-round 
Delphi survey followed by a face-to-face consensus panel meeting of 13 
HCPs and 8 patients.  
Results: The final COS included 19 outcomes. Twelve apply to all 
interventions: death from prostate cancer, death from any cause, local 
disease recurrence, distant disease recurrence/metastases, disease 
progression, need for salvage therapy, overall quality of life, stress urinary 
incontinence, urinary function, bowel function, faecal incontinence, sexual 
function. Seven were intervention-specific: perioperative deaths (surgery), 
positive surgical margin (surgery), thromboembolic disease (surgery), 
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bothersome or symptomatic urethral or anastomotic stricture (surgery), 
need for curative treatment (active surveillance), treatment failure 
(ablative therapy), and side effects of hormonal therapy (hormone 
therapy). The UK-centric participants may limit the generalisability to other 
countries, but trialists should reason why the COS would not be applicable. 
The default position should not be that a COS developed in one country will 
automatically not be applicable elsewhere.  
Conclusion: We have established a COS for trials of effectiveness in 
localised prostate cancer, applicable across all interventions which should 
be measured in all localised prostate cancer effectiveness trials.  
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A core outcome set for localised prostate cancer effectiveness trials 1 
Word count: 3,151  2 
1. Introduction  3 
Treatments for localised prostate cancer can be associated with side effects such as urinary 4 
incontinence, erectile dysfunction or bowel dysfunction. These may be permanent and cause 5 
significant impairment of quality of life. (1) The choice between treatments is driven by the 6 
therapeutic ratio with a balance between cancer control and the likelihood of experiencing adverse 7 
events, speed of return to routine activities and long-term impact on health-related quality of life. 8 
(2, 3) 9 
It is therefore critical that outcomes important to all stakeholders are measured and reported. 10 
However, many systematic reviews of effectiveness (4-9) and clinical practice guidelines (10) 11 
acknowledge the difficulties in synthesising the evidence base due to heterogeneity in outcome 12 
selection, definitions, measurement and reporting across different trials.  13 
A potential solution is a “core outcome set” (COS), which is a minimum set of outcomes that should 14 
be measured and reported in effectiveness trials in a particular condition. (11) Its use can reduce 15 
heterogeneity in outcome selection, measurement and reporting across trials, and facilitate 16 
evidence synthesis. (12, 13) 17 
A ‘standard set of patient-centred’ outcomes was developed by Martin et al (14). However, Martin 18 
et al’s purpose was to provide quality indicators for institutional registries, “outside of clinical trials” 19 
(15) with which clinicians or hospitals may measure themselves competitively to “drive competition 20 
around value”.  As such, their work was not a COS for effectiveness trials. (14) Furthermore, the 21 
inclusion of only two patients in Martin et al’s consensus process is unlikely to be sufficient and may 22 
have biased any results toward clinician preference. (16) Lastly, the tools used to measure their 23 
standard set were not evaluated transparently or robustly with regards to measurement properties 24 
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and feasibility. (13) It is currently unclear which measures should be used in the outcomes measured 25 
in clinical trials. 26 
We report here the results of the development and establishment of a COS for intervention 27 
effectiveness trials for localised prostate cancer. The intention was to identify core outcomes which 28 
were applicable across all intervention and outcomes which may be intervention-specific. The scope 29 
of the project led to the appropriate methods (outlined below) which are advocated by the COMET 30 
initiative, (11, 12) and are explained further in our study protocol. (17) We report our study in line 31 
with the COS-STAR reporting guidance. (18) 32 
1.2 Aims and objectives 33 
The aim was to establish a COS for trials of primary interventions for localised prostate cancer 34 
(defined as clinical TNM stage ≤T2N0M0) (19) which is applicable across all interventions, including 35 
adjuvant hormonal therapy.   36 
Specific objectives were to:  37 
1. Achieve consensus amongst patients and healthcare professionals on outcomes critically 38 
important to decision-making; and 39 
2. Establish a COS for use in future trials assessing interventions for localised prostate cancer. 40 
2. Materials and Methods 41 
2.1 Protocol registration and ethical approval 42 
The methodology used was that recommended by the COMET Initiative – the international expert 43 
body dedicated to the robust development of COS. (20) The study protocol was published (17) and 44 
the study approved by the National Research Ethics Service (NRES) – North of Scotland Committee 45 
(reference 12/NS0042). A project steering committee was established to provide oversight. 46 
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2.2 Achieving consensus amongst patients and healthcare professionals on critically 47 
important outcomes  48 
The consensus building process was divided into two phases: (1) Delphi survey involving prostate 49 
cancer patients in the UK, and healthcare professionals (HCPs) involved in the management of 50 
localised prostate cancer across the UK, Europe and the USA; and (2) formal consensus group 51 
meeting involving patients and HCPs.  52 
2.2.1 Delphi survey 53 
Delphi surveys are a well-recognised and increasingly-used consensus method for COS development. 54 
(21)  A systematic review of the literature was initially performed to ascertain the full range of 55 
outcomes that had previously been reported in trials of interventions for localised prostate cancer. 56 
(22) In addition, semi-structured interviews were conducted with a purposive sample of patients to 57 
identify any further potentially relevant outcomes. (22)  All identified outcomes where entered into 58 
a bespoke online Delphi tool, written in C# using WebForms and a MySQL backend. The full list of 59 
outcomes included in the questionnaire (and their definitions) is shown in Appendix 1. Survey 60 
participants rated each of the items’ importance for decision-making. 61 
Patients and HCPs were chosen because they are important stakeholders in the management of 62 
localised prostate cancer. Participants from the UK were primarily targeted due to feasibility and 63 
resource issues. Patients were eligible if they had been treated or managed for localised prostate 64 
cancer and were identified through the UK-based UCAN charity’s prospective patient database (23) 65 
and through prostate cancer support groups registered in the UK and listed on the National 66 
Federation of Prostate Cancer Support Groups’ website. (24) HCPs were identified through the 67 
following membership directories and websites: British Association of Urological Surgeons (BAUS), 68 
British Association of Urological Nurses (BAUN), European Society for Medical Oncology (ESMO), 69 
American Society of Clinical Oncology (ASCO), European Association of Urology Guidelines Office, 70 
and the Cochrane Urology group. Purposive sampling was undertaken, covering different 71 
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treatments, age and time since treatment for patients, and type of HCP (urologist, oncologist, or 72 
cancer nurse specialist) and area of expertise (robotic or laparoscopic radical prostatectomy, ablative 73 
therapy, external beam radiotherapy, brachytherapy, and active surveillance).  153 patients and 110 74 
HCPs were invited, with an anticipated completion rate of 50%. Informed consent was presumed if 75 
participants registered to take part in the online survey. 76 
The questionnaires and participant information sheets were assessed for face validity in a focus 77 
group with 6 patients and 5 HCPs. Three iterative rounds were planned, and after round one, 78 
participants were reminded of their own scores and provided with feedback from within their own 79 
groups and/or from the other groups. Participants had the opportunity to revise their score, or add 80 
further items into the survey for incorporation in the following round. No items were dropped 81 
between rounds. Participants were asked to score the importance of each outcome listed on a 9-82 
point scale adapted from GRADE (25) (i.e. 1-3 = not important; 4-6 = important; 7-9 = critical; 83 
together with an ‘unable to score’ option). 84 
Descriptive statistics were used to summarise the results of each round, including the percentage of 85 
participants scoring each of 1-9 for the outcome. The results for each stakeholder group were 86 
analysed and presented separately in each round. After the final round, items scored as critical (i.e. 87 
7-9) by ≥70% of patients and HCPs separately AND not important (i.e. 1-3) by <15% of patients and 88 
HCPs separately were eligible for inclusion in a preliminary core outcome set (i.e. ‘consensus in’ 89 
outcomes). Conversely, items scored as not important (i.e. 1-3) by ≥70% of patients and HCPs 90 
separately and critical (7-9) by <15% of patients and HCPs separately were excluded from further 91 
analysis (i.e. ‘consensus out’ outcomes). All other outcomes were classified as ‘equivocal’. These 92 
scoring thresholds were based prior COS projects. (26-28) All outcomes were available for discussion 93 
and voted on at the consensus group meeting.  94 
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2.2.2 Consensus group meeting 95 
A one-day consensus group meeting was held to review the preliminary COS derived from the Delphi 96 
survey, and to discuss, deliberate and vote in order to establish the final COS. Patients and HCPs 97 
were purposively sampled from those completing all rounds of the Delphi survey to ensure 98 
representation of patients receiving the range of treatment types, and urologists, oncologists and 99 
cancer nurse specialists. Non-voting observers, a patient and public involvement coordinator (PPI), 100 
and non-clinical members of the project steering group also attended. The meeting was chaired by a 101 
member of the Steering Group [PRW]. 102 
Voting was undertaken anonymously using personalised electronic handsets. (29) All items were 103 
individually presented, reviewed, discussed and voted upon regarding their importance for decision-104 
making. Participants were asked “Is this outcome important enough to be included in the COS?” and 105 
asked to score the outcomes on the same 1-9 scale as the Delphi survey.  Items scored as critical (i.e. 106 
7-9) by ≥70% and not important (i.e. 1-3) by <15% of voting members were eligible for inclusion in 107 
the final COS. The results for an outcome were conveyed to participants immediately after voting, 108 
and the final COS was shown to all participants at the end of the meeting.  109 
3. Results 110 
An overview of the COS development process and summary of results can be seen in Figure 1.  111 
3.1 Consensus amongst patients and healthcare professionals on critically important 112 
outcomes 113 
3.1.1 Delphi survey  114 
The systematic review and patient interviews generated 79 discrete outcomes which were 115 
incorporated into an online questionnaire (Appendix 1). A total of 152 participants completed all 3 116 
rounds of the survey. Of these, 47 (31%) were HCPs and 105 (69%) were patients. The completion 117 
rate (i.e. proportion who completed all 3 rounds of the survey out of those invited) was 43% for 118 
Page 8 of 40BJU International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
 
HCPs and 69% for patients.  The overall attrition rate (i.e. drop outs between rounds 1 and 3) was 119 
13%. We investigated whether attrition may have introduced bias by comparing the mean (SD) 120 
round 1 scores for those completing round 1 and round 2 (5.9 (1.3)) with those who dropped out 121 
after round 1 (5.8 (1.5)). We then repeated this for mean (SD) round 2 scores for those completing 122 
round 2 and 3 (6 (1.2)), compared with those who dropped out after round 2 (5.7 (0.7)). Those 123 
dropping out between rounds did not appear to hold different views, suggesting that there was no 124 
attrition bias.   125 
Tables 1a and 1b summarise the treatment/expertise characteristics of the patients and HCPs who 126 
completed all 3 rounds of the survey. In addition, the detailed characteristics of HCPs completing all 127 
3 rounds are included in Appendix 2. Five additional outcomes were proposed by participants in 128 
round 1 (impact on relationship with partner, bladder pain, urinary tract infection, induction of new 129 
cancers, and side effects of hormonal therapy), and these were incorporated into subsequent 130 
rounds. Table 2 summarises the results from Delphi survey round three, showing how each outcome 131 
was finally scored by patients and HCPs with the results expressed as proportions for each category 132 
of ‘not important’, ‘important’, and ‘critical’, for the entire study cohort. The outcomes which 133 
fulfilled the criteria for ‘consensus in’, and ‘equivocal’ outcomes are indicated. No outcomes met the 134 
criteria for ‘consensus out’.  135 
3.1.2 Consensus group meeting  136 
The consensus group meeting was held at the University of Aberdeen, Scotland on the 22
nd
 February 137 
2016. A total of 21 voting members attended (8 patients, 13 HCPs). The list of participants along with 138 
their expertise is given in Table 3. For patients, the median [IQR] time since treatment was 3.5 [2.6-139 
4.3] years. The complete results of the Delphi survey were presented and discussed.  140 
Following discussion, four outcomes (urinary function, bowel function, sexual function and overall 141 
quality of life) were grouped back into broader domains. This was done because there was a split 142 
vote i.e. that everyone voted some aspect of those domains as critical (7-9) but not all voted for the 143 
Page 9 of 40 BJU International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
7 
 
same aspect.  Consequently, this was a pragmatic means of taking into account the heterogeneity of 144 
responses from the Delphi survey and consensus meeting in regard to those discrete outcomes 145 
Therefore, these multi-dimensional outcomes will need careful consideration of appropriate 146 
measurement instruments – which is part of the planned future research. The original categories for 147 
urinary function, bowel function, sexual function and overall quality of life outcomes before re-148 
categorisation can be viewed in Appendix 1.   149 
The results of the voting for each outcome are summarised in Appendix 3. The final core outcome 150 
set is summarised in Table 4, along with the interventions each core outcome is relevant to. The final 151 
COS contains 19 outcomes, with 12 universal outcomes (i.e. relevant across all interventions) and 7 152 
intervention-specific ones (4 for surgery, and one each for active surveillance, 153 
cryotherapy/HIFU/ablative therapy, and hormonal therapy).  154 
Discussion 155 
Our study adopted robust methods to generate a core outcome set relevant to trials of interventions 156 
for localised prostate cancer.  From the consensus process, 19 core outcomes were identified: 12 157 
universal and 7 intervention-specific, covering all domains of cancer control and survival, urinary 158 
function, bowel function, sexual function, quality of life, and adverse events.  159 
There have been two recent reports on developing standardised outcomes in the field of localised 160 
prostate cancer. Martin et al. (14) defined a set of health outcomes for localised prostate cancer 161 
management, to be measured in routine clinical practice with the purpose of determining the value 162 
of health care interventions;  (14) and van den Bos et al. (30) reported on a consensus statement 163 
regarding the design of future trials of focal ablative therapy for a sub-set of patients with localised 164 
prostate cancer.  Additional insights provided by our study are that it is the first localised prostate 165 
cancer study that takes into account the opinions of patients on a large scale and uses robust and 166 
transparent methods planned a priori.  167 
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Whilst it is encouraging that there is broad overlap between Martin et al’s outcomes recommended 168 
for clinical practice and our COS for effectiveness trials, it is important to reiterate the differences in 169 
the aims of the two studies, i.e. we aimed to develop a COS for effectiveness trails, Martin et al’s 170 
standard-set was not designed for trials but for routine clinical practice. It is important also to re-171 
state the methodological differences. In particular the involvement of only two patients in Martin et 172 
al’s consensus process is unlikely to sufficiently capture patient opinion. (15, 16, 31) Ultimately, it is 173 
desirable for routine clinical data and data from trials to be commensurable, particularly in situations 174 
where routine data (such as rare events) might be more reliably captured in long-term institutional 175 
databases as opposed to the trial setting.  176 
Van den Bos et al’s recommended primary outcome measure (negative biopsy at 12 months after 177 
treatment) (30) is encompassed within our outcome of treatment failure for ablative therapy in our 178 
COS. There are important differences between this study and our COS study. First, our COS study 179 
had a broader scope encompassing all current treatments for localised prostate cancer rather than a 180 
single type of intervention for a subset of patients with certain disease characteristics. Also, their 181 
expert group had no patient representation; the Delphi process does not give adequate information 182 
to assess how information was fed back to participants between rounds, and may have influenced 183 
subsequent rounds; and it is unclear how consensus was reached in the final meeting. (32) 184 
This study is the most rigorous and largest of its kind, involving a large sample of patients from the 185 
UK, and HCPs from the UK, Europe and USA, producing a COS specifically developed for localised 186 
prostate cancer intervention trials using rigorous, protocol-driven, transparent and reproducible 187 
methods. (17) A comprehensive and robust systematic review to explore, define and characterise 188 
the nature of heterogeneity of outcome selection, definition and measurement was performed prior 189 
to a consensus-based process involving a Delphi survey and a consensus group meeting. The study 190 
involved a large, purposively sampled group of participants which included men with localised 191 
prostate cancer, and a diverse group of healthcare professionals from the UK, Europe and the USA.  192 
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The Delphi survey included three iterative rounds, whereby feedback on others’ opinions was 193 
provided to allow participants to reflect, and to revise or maintain their responses as required, in 194 
addition to proposing any additional outcomes.  195 
A limitation of the COS is that most of the participants were from the UK. However, we think that 196 
people in other countries should look at this well-developed COS and ask the question ‘Is there a 197 
reason why these results would not be similar to those that could be obtained in our population?’ If 198 
the answer is yes, then clearly more work is needed, but the default position should not be that a 199 
COS developed in one country will automatically not be applicable elsewhere. Additionally, more 200 
surgeons completed the survey and participated in the consensus meeting than oncologists. 201 
However, the HCP group also consisted of specialist nurses who provided crucially important 202 
perspectives regarding treatment with radiotherapy. 203 
We assumed that most potentially important outcomes were likely to be reported in studies 204 
representing the highest levels of evidence only, based on the hierarchy of evidence, (33) on the 205 
basis that such studies are more likely to guide or change practice, and more likely to measure 206 
outcomes using validated tools. Although this may be considered a strength, it can also be regarded 207 
as a limitation because some potentially important outcomes may have been missed from our 208 
review. However, this risk is minimised by supplementing the long list of potentially important 209 
outcomes with additional outcomes identified from the semi-structured patient interviews, and 210 
from the Delphi survey where additional outcomes could be added.   211 
The problems and issues arising from inconsistency and heterogeneity of outcome selection, 212 
definition, measurement and reporting in primary and secondary studies of localised prostate cancer 213 
are well documented. (4, 5, 7, 34, 35) Prospective trials of interventions for localised prostate 214 
cancer, should consider adopting the COS. Using our COS, future trialists have an opportunity to 215 
omit other outcomes which are not ‘core’, thereby reducing the burden on trialists, patients and 216 
funders. Some steps have been directed toward the implementation of the COS inasmuch as the COS 217 
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is listed in the COMET database and COMET is targeting trial funders (e.g. NIHR guidance) and 218 
trialists (e.g. SPIRIT guidelines) to use COS, where they exist for planned trials.  219 
Additional outcomes beyond the COS proposed (e.g. economic outcomes, related to use of health 220 
services, or specific surgical outcomes such as blood loss or anastomotic leak) might need to be 221 
measured to address questions beyond relative effectiveness, as these outcomes may be 222 
determinants of the cost and effectiveness components of a cost-effectiveness analysis.(36) There is 223 
also a valid argument for adopting the COS in clinical practice, since it reflects outcomes of greatest 224 
importance to patients and HCPs in making healthcare decisions. There is evidence that COS for 225 
trials align very closely with those required for informed consent (37).  226 
Future work should focus on how the COS should be defined and measured in practice, 227 
incorporating elements such as standardising outcome definitions and thresholds, identifying the 228 
most appropriate measurement instruments, and time points for outcome assessment. We plan to 229 
address this in the next phase of our project, based on a strategy of appraising existing outcome 230 
measurement tools using objective criteria, such as those outlined in the OMERACT filter (36) or 231 
recommended by COSMIN. (13) 232 
In conclusion, our study reports on the robust development of a comprehensive core outcome set 233 
for use in trials assessing interventions for localised prostate cancer. The final core outcome set 234 
includes 19 core outcomes, with 12 universal and 7 intervention-specific.  The routine adoption of 235 
this COS in future trials of interventions for localised prostate cancer should ensure that outcomes of 236 
importance to patients and healthcare professionals will be collected and thus facilitate comparisons 237 
across different studies to allow informed treatment choices for patients, health care professionals 238 
and service providers.  239 
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Table 1a: Summary of characteristics of patients who completed all three rounds of the Delphi survey 
Patients (N = 105) 
Age N (%) Primary treatment N (%) Time since treatment N (%) Country of origin N (%) 
≤60 years >60 years Surgery EBRT Brachytherapy AS Ablative therapy ≤1 year 2-5 years >5 years Scotland England Wales  
19  (18) 86 (82) 50 (48) 26 (25) 7 (7) 17 (16) 5 (5) 17 (16) 53 (51) 35 (33) 20 (19) 72 (69) 13 (12) 
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Table 1b: Summary of characteristics of HCPs who completed all three rounds of the Delphi survey 
HCPs (N = 47) 
Expertise N (%) Country of origin N (%) 
CNS Urological surgeon Oncologist Scotland England Wales Other European countries USA 
8 (17) 31 (66) 8 (17) 25 (53) 12 (26) 1 (2) 7 (15) 2 (4) 
Abbreviations: HCPs (health care professionals) CNS (cancer nurse specialist), EBRT (electron beam radiotherapy), AS (active surveillance) 
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Table 2: Summary of results after three rounds of Delphi survey 
Outcomes  
Patients N = 105 HCPs N =  47 
Consensus 
from Delphi 
survey  
Not 
important Important Critical 
Not 
important Important Critical 
A.CANCER SPECIFIC AND SURVIVAL OUTCOMES 
1. Death from any cause 2% 6% 92% 0% 2% 98% In  
2. Death from prostate cancer 1% 4% 95% 0% 2% 98% In  
3. Death from causes other than prostate cancer* 2% 9% 89% 0% 6% 94% In  
4. Local disease recurrence 1% 5% 94% 0% 4% 96% In  
5. Distant disease recurrence/metastases 1% 3% 96% 0% 0% 100% In  
6. Disease progression (disease getting worse) 2% 5% 93% 0% 4% 96% In  
7. Need for further treatment to augment primary treatment 2% 10% 88% 0% 19% 81% In  
8. Need for salvage therapy 3% 6% 91% 0% 13% 87% In  
Applicable to active surveillance  
9. Disease reclassification 5% 6% 89% 0% 23% 77% In  
10. Need for curative treatment 5% 9% 86% 0% 4% 96% In  
Applicable to ablative procedures (cryotherapy, HIFU) 
11. Treatment failure 4% 4% 93% 0% 11% 89% In  
12. Retreatment 4% 8% 88% 0% 19% 81% In  
Applicable to surgery 
13. Positive surgical margin 3% 5% 92% 4% 49% 47% Equivocal 
B. BOWEL FUNCTION 
14. Diarrhoea 7% 82% 11% 2% 87% 11% Equivocal  
15. Faecal incontinence 4% 19% 77% 2% 9% 89% In  
16. Faecal urgency 4% 57% 39% 2% 63% 35% Equivocal  
17. Rectal bleeding 6% 38% 56% 4% 57% 39% Equivocal  
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18. Rectal itch 15% 79% 6% 15% 80% 4% Equivocal  
19. Constipation 10% 80% 9% 11% 85% 4% Equivocal  
20. Bowel frequency 13% 83% 4% 7% 85% 9% Equivocal  
21. Painful bowel movements 9% 64% 27% 2% 83% 15% Equivocal  
C. URINARY FUNCTION 
22. Urge incontinence 6% 44% 50% 0% 43% 57% Equivocal  
23. Stress incontinence 7% 60% 33% 0% 49% 51% Equivocal  
24. Weak urine stream 10% 79% 11% 7% 87% 7% Equivocal  
25. Nocturia 26% 60% 14% 7% 87% 7% Equivocal  
26. Haematuria 11% 37% 52% 9% 83% 9% Equivocal  
27. Dysuria 9% 53% 38% 2% 91% 7% Equivocal  
28. Frequency 17% 68% 14% 11% 83% 7% Equivocal  
29. Urgency 11% 67% 22% 2% 89% 9% Equivocal  
30. Need for a temporary urethral catheter 27% 34% 39% 23% 72% 4% Equivocal  
31. Catheter-related problems 10% 40% 49% 13% 79% 9% Equivocal  
D. SEXUAL FUNCTION 
32. Erectile dysfunction 10% 52% 38% 0% 68% 32% Equivocal  
33. Reduced or loss of libido 8% 66% 26% 0% 94% 6% Equivocal  
34. Frequency of intercourse 14% 72% 14% 9% 89% 2% Equivocal  
35. Ejaculatory function 18% 60% 22% 21% 79% 0% Equivocal  
36. Orgasmic function 10% 63% 27% 2% 98% 0% Equivocal  
37. Sexual function 10% 61% 29% 0% 83% 17% Equivocal  
E. OPERATION SPECIFIC AND HOSPITAL-STAY OUTCOMES 
Applicable to all treatments apart from Active surveillance 
38. Duration of the procedure 39% 57% 4% 49% 51% 0% Equivocal  
39. Pain 10% 82% 8% 0% 100% 0% Equivocal  
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40. Use of pain relief medications after procedure 8% 82% 10% 9% 91% 0% Equivocal  
41. Catheter duration 13% 71% 16% 17% 83% 0% Equivocal  
42. Duration of hospital stay 34% 61% 5% 13% 87% 0% Equivocal  
43. Time to full recovery 14% 71% 15% 0% 52% 48% Equivocal  
44. Time to partial recovery 17% 76% 7% 4% 93% 2% Equivocal  
Applicable to radical prostatectomy only 
45. Blood loss 18% 56% 26% 2% 82% 16% Equivocal  
F. QUALITY OF LIFE AND EMOTIONAL WELL-BEING 
46. Anxiety 14% 78% 9% 2% 89% 9% Equivocal  
47. Depression 12% 69% 19% 2% 89% 9% Equivocal  
48. Lack of confidence 16% 73% 11% 2% 89% 9% Equivocal  
49. Feeling less masculine 27% 61% 12% 2% 91% 6% Equivocal  
50. Feeling tired or fatigued 10% 73% 17% 0% 94% 6% Equivocal  
51. Overall Quality of LIfe 11% 52% 37% 0% 40% 60% Equivocal  
52. Quality of life relating to urinary function 8% 56% 37% 0% 49% 51% Equivocal  
53. Quality of life relating to sexual function 8% 64% 28% 0% 77% 23% Equivocal  
54. Quality of life relating to bowel function 6% 48% 45% 0% 49% 51% Equivocal  
55. Quality of life impact on immediate family 6% 56% 38% 0% 79% 21% Equivocal  
G. ADVERSE EVENTS DURING AND AFTER HORMONE THERAPY  
56. Hot flushes 26% 72% 2% 4% 91% 4% Equivocal  
57. Swelling of the breast tissue (gynaecomastia) 17% 70% 13% 4% 87% 9% Equivocal  
58. Loss of libido 16% 70% 14% 2% 98% 0% Equivocal  
59. Erectile dysfunction 17% 53% 29% 2% 85% 13% Equivocal  
60. Body fat gain 7% 76% 17% 4% 91% 4% Equivocal  
61. Fatigue 3% 77% 21% 2% 81% 17% Equivocal  
H. ADVERSE EVENTS DURING AND AFTER RADIATION THERAPY 
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62. Anal discomfort 8% 82% 10% 0% 96% 4% Equivocal  
63. Urethral stricture 8% 21% 71% 0% 47% 53% Equivocal 
64. Radiation proctitis 9% 52% 39% 0% 53% 47% Equivocal  
65. Acute urinary retention 12% 8% 80% 0% 45% 55% Equivocal 
66. Fatigue 7% 84% 9% 0% 81% 19% Equivocal  
67. Haematuria 15% 60% 25% 4% 77% 19% Equivocal  
I. ADVERSE EVENTS DURING AND AFTER SURGERY  
68. Acute or sub-acute bowel obstruction 10% 8% 82% 0% 29% 71% In  
69. Acute urinary retention 6% 14% 80% 0% 42% 58% Equivocal 
70. Anastomotic leak 8% 18% 74% 0% 64% 36% Equivocal  
71. Blood transfusion 11% 42% 47% 2% 64% 33% Equivocal  
72. Wound problems 8% 38% 55% 2% 89% 9% Equivocal  
73. Bowel injury 6% 13% 81% 0% 11% 89% In  
74. Nerve damage or neuropraxia 8% 20% 72% 0% 53% 47% Equivocal  
75. Perioperative deaths 7% 1% 91% 0%   100% In  
76. Prolonged indwelling catheter 6% 31% 63% 7% 80% 13% Equivocal  
77. Thromboembolic disease 8% 3% 89% 0% 11% 89% In  
78. Rectourethral fistula 8% 5% 88% 0% 4% 96% In  
79. Urethral or anastomotic stricture 6% 12% 83% 0% 24% 76% In  
Additional outcomes suggested by participants in Round 1 
80. Impact on relationship with partner 10% 45% 46% 0% 57% 43% Equivocal  
81. Bladder pain  19% 45% 36% 2% 89% 9% Equivocal  
82. Urinary tract infection  19% 46% 36% 6% 89% 4% Equivocal  
83. Induction of new cancers+ 9% 5% 86% 2% 53% 45% Equivocal 
84. Side effects of hormonal therapy  6% 31% 63% 0% 46% 54% Equivocal  
Key: Green cells indicate outcomes meeting consensus ‘in’. Red cells indicate ≥70% critical 
*’Death from causes other than prostate cancer’ was originally voted ‘in’, but after discussion it was felt to be structurally related to ‘death from any cause’ and ‘death from prostate cancer’ and therefore voted out.  
Page 22 of 40BJU International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
+‘Induction of new cancers’ was originally voted ‘in’ but after discussion it was felt to be too rare and late occurring an outcome to be feasibly collected in a trial setting and therefore voted out.  
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Table 3: Expertise and experience of consensus meeting participants 
Name Role Expertise/Experience Date of 
treatment start 
City, country 
Gary Akehurst  Patient Received treatment for localised prostate cancer November 2011 England (UK) 
Robert 
Almquist 
Patient Received treatment for localised prostate cancer November 2013 England (UK) 
Karl Beck Patient Received treatment for localised prostate cancer January 2008 Scotland (UK) 
David Budd Patient Received treatment for localised prostate cancer June 2013 Scotland (UK) 
Alexander Ewen Patient Received treatment for localised prostate cancer November 2013 Scotland (UK) 
David Hurst Patient Received treatment for localised prostate cancer September 
2011 
England (UK) 
Andrew Mackie Patient Received treatment for localised prostate cancer June 2012 Scotland (UK) 
Hans Schreuder Patient Received treatment for localised prostate cancer October 2012 England (UK) 
Hashim Ahmed HCP (Surgeon) HIFU NA London, England 
(UK) 
James N'Dow HCP (Surgeon)/ European Association of 
Urology Guidelines Office 
 
Surgery and active surveillance/ Chair of EAU 
Guidelines Office 
NA Aberdeen, 
Scotland (UK) 
Judith Grant HCP (Clinical Oncologist) EBRT and active surveillance NA Aberdeen, 
Scotland (UK) 
Justine Royle HCP (Surgeon) Robotic/laparoscopic radical prostatectomy NA Aberdeen, 
Scotland (UK) 
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Kevin Wardlaw HCP (CNS) Prostate cancer management NA Aberdeen, 
Scotland (UK) 
Nicolas Mottet  HCP (Surgeon)/European Association of 
Urology Prostate cancer guideline panel 
Laparoscopic radical prostatectomy/Chair of EAU 
Prostate cancer guideline panel 
NA St. Etienne, 
France 
Philip Cornford HCP (Surgeon)/European Association of 
Urology Prostate cancer guideline panel 
Robotic radical prostatectomy/Co-chair of EAU 
Prostate cancer guideline panel 
NA Liverpool, 
England (UK) 
Philip Dahm HCP (Surgeon)/Cochrane Urology editorial 
group 
Open radical prostatectomy/Coordinating  Editor 
of Cochrane Urology 
NA Minneapolis, USA 
Rakesh Heer HCP (Surgeon) Robotic radical prostatectomy NA Newcastle, 
England (UK) 
Rob Jones HCP (Medical Oncologist)/Cancer Research 
UK Clinical Trials Unit 
Active surveillance, Director of CRUK CTU, Beatson 
Institute 
NA Glasgow, 
Scotland (UK) 
Sam McClinton HCP (Surgeon) Surgery and active surveillance NA Aberdeen, 
Scotland (UK) 
Thomas Lam HCP (Surgeon) Robotic/laparoscopic radical prostatectomy 
 
NA Aberdeen, 
Scotland (UK) 
William Cross HCP (Surgeon) Robotic radical prostatectomy NA Leeds, England 
(UK) 
Marion 
Campbell 
Methodologist (Non-voting)/Health Services 
Research Unit 
Evidence synthesis and trials/Chair of Health 
Services Research Unit, Aberdeen 
NA Aberdeen, 
Scotland (UK) 
Paula 
Williamson 
Chair  
Methodologist (Non-voting)/COMET 
Evidence synthesis, trials and COS/Chair of COMET 
Initiative Management Group 
NA Liverpool, 
England (UK) 
Steven 
MacLennan 
Methodologist (Non-voting)  Evidence Synthesis and qualitative research NA Aberdeen, 
Scotland (UK) 
Linda Pennet  PPI/CNS (Non-voting) Prostate cancer management NA Aberdeen, 
Scotland (UK) 
Grigoris 
Athanasiadis 
Observer  Robotic radical prostatectomy NA Aberdeen, 
Scotland (UK) 
Rebecca Fish  Observer  Colorectal surgeon and PhD student developing 
COS in anal cancer 
NA Bristol, England 
(UK) 
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Abbreviations: HIFU (high intensity focussed ultrasound), EBRT (electron beam radiotherapy), COS (core outcome set), HCP (healthcare professional), UCAN 
(urological cancer charity), PCASO (prostate cancer support organisation), LPC (localised prostate cancer), PPI (patient and public involvement) 
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Table 4: Final Core Outcome Set for trials of interventions for localised prostate cancer 
Domain  Outcome 
Universal (i.e. applicable to all interventions) 
Cancer/survival Death from prostate cancer 
Cancer/survival Death from any cause 
Cancer/survival Local disease recurrence  
Cancer/survival Distant disease recurrence/metastases  
Cancer/survival Disease progression  
Cancer/survival Need for salvage therapy  
Bowel function Faecal incontinence  
Bowel function Bowel function (including diarrhoea, faecal urgency, rectal bleeding, rectal itch, constipation, bowel frequency, and painful bowel 
movements) 
Urinary 
function 
Stress incontinence  
Urinary 
function 
Urinary function (including urge incontinence, weak urine stream, nocturia, haematuria, dysuria, frequency, urgency, need for temporary 
catheter, and catheter related problems) 
Sexual function Sexual function (including erectile dysfunction, reduced or loss of libido, frequency of intercourse, ejaculatory function, orgasmic 
function, and sexual function,) 
Quality of life Overall quality of life (including anxiety, depression, lack of confidence, feeling less masculine, feeling tired or fatigued, overall quality of 
life, quality of life relating to urinary function, quality of life relating to sexual function, quality of life relating to bowel function and 
quality of life impact on immediate family) 
Surgery (i.e. radical prostatectomy) 
Cancer/Survival Positive surgical margin  
Adverse events  Perioperative deaths  
Adverse events Thromboembolic disease  
Adverse events Bothersome or symptomatic urethral or anastomotic stricture 
Ablative therapy 
Cancer/survival Treatment failure 
Active surveillance 
Cancer/survival Need for curative treatment  
Hormone Therapy 
Adverse events Side effects of hormonal therapy 
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Figure 1: Overview of core outcome set development 
 
 
 
 
 
 
Generation of outcomes list  
Systematic review:   
1415 verbatim outcomes 
 
List of 79 outcomes  
Delphi Round 1 
79 outcomes scored 
5 additional outcomes identified  
 
Generation of outcomes list: 
Patient interviews 
3 additional outcomes 
Delphi Round 2 
84 outcomes scored  
  
Delphi Round 3 
84 outcomes scored  
  
Consensus meeting 
84 outcomes discussed  
  
17366 abstracts and 2080 full 
texts screened   
325 studies included  
15 semi-structured interviews 
   
110 HCPs and 153 patients 
invited  
56 HCPs and 118 patients 
completed 
 
47 HCPS and 105 patients 
completed 
   
49 HCPs and 109 patients 
completed 
   
13 HCP and 8 patient voting 
participants 
   
Final core outcome set 
12 (all interventions): death from prostate cancer, death from any cause, 
local disease recurrence, distant disease recurrence/metastases, disease 
progression, need for salvage therapy, overall quality of life, stress urinary 
incontinence, urinary function,  bowel function, faecal incontinence, sexual 
function 
   
7 (intervention specific): perioperative deaths (surgery), positive surgical 
margin (surgery), thromboembolic disease (surgery), bothersome or 
symptomatic urethral or anastomotic stricture (surgery) need for curative 
treatment (active surveillance), treatment failure (ablative therapy), and 
side effects of hormonal therapy (hormone therapy) 
Categorising outcomes in 
domains:  
76 outcomes 
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Appendix 1. Round one questionnaire including list of outcomes to score and definitions 
 
Please score the following outcomes. On each page you will see a list of outcomes organised under heading such as ‘adverse events’ or ‘bowel function ‘and 
you will be asked to score them on a scale of 1-9, with 1 being not important at all and 9 being critically important. We have split some of the adverse 
events (also known as ‘side-effects’) up by the type of treatments that people might have because the adverse events are not exactly the same for each 
treatment type. Some me might have had only surgery or radiotherapy as part of their treatment, where as some men might have had both, and other men 
may have had hormone treatment too.  Even if you didn’t have a particular treatment, you might still like to score these outcomes because they might have 
been important in making decisions about which treatment to have.  If you feel you can’t answer, just click ‘unable to score’. Please specify any other 
important outcomes, in the space provided in the last row under ‘Other’ and remember to score any new outcomes you suggest. 
 
A. Cancer-specific outcomes and survival outcomes  
  Not 
important 
Important  Critical   
Outcome Lay description  1 2 3 4 5 6 7 8 9 Unable 
to 
score 
Applicable to all treatments 
1. Death from any cause This outcome refers to the death of someone from any cause, including prostate cancer.           
2. Death from prostate 
cancer 
This outcomes refers to the death of someone as a result of prostate cancer           
3. Death from causes other 
than prostate cancer 
This outcome refers to the death of someone from any causes other than prostate cancer.           
4. Local disease recurrence This outcome indicates that the disease has come back locally either within the prostate, or in the 
surrounding area (i.e. prostate bed), following a previous cure. This includes a range of different 
measures, including radiological imaging combined with biopsies, the use of PSA as an indicator, positive 
repeat biopsies 1 year after ablative therapy (e.g. cryotherapy, HIFU, etc.), positive repeat biopsies after 
curative radiotherapy, etc. 
          
5. Distant disease 
recurrence/metastases 
This outcome refers to someone whose cancer has spread to other parts of their body (e.g. bones, lymph 
nodes, etc.). 
          
6. Disease progression 
(disease getting worse) 
This outcome refers to the progression of someone’s cancer and is based on a combination of factors 
including PSA changes and/or clinical indicators of progression (i.e. disease getting worse) such as 
radiological imaging combined with biopsies, etc. 
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7. Need for further 
treatment to augment 
primary treatment 
This outcome refers to the need for a person to have additional treatment following a curative treatment. 
Examples include use of radiotherapy following surgery, hormonal therapy after radiotherapy, hormonal 
therapy after ablative therapy (e.g. HIFU, cryotherapy), etc. 
          
8. Need for salvage therapy This outcome refers to the need for a person to have additional curative treatment for disease which has 
come back (i.e. recurred), following a previous cure. 
          
Applicable to active surveillance 
9. Disease reclassification This refers to the upgrading of a person’s cancer on repeat prostate biopsies (i.e. indicating that the 
disease has become more aggressive), or repeat radiological imaging (usually based on MRI scan) has 
shown more extensive or more aggressive disease. This usually triggers the need for curative treatment 
on patients managed initially by active surveillance. 
          
10. Need for curative 
treatment 
This refers to people who have needed curative treatment during the period of active surveillance.           
Applicable to ablative procedures (cryotherapy, HIFU)  
11. Treatment failure This outcome refers to the presence of cancer after one or more treatments, confirmed by radiological 
imaging (i.e. persistent disease, usually detected using MRI) or biopsy, or both. This can be performed at 
different time points following treatment. At some time points, this outcome can lead to repeat 
treatment of the same procedure (i.e. re-treatment); at longer time points (e.g. more than 1 year), it is 
regarded as failure of treatment, and leads to the need for a different curative treatment (i.e. salvage 
treatment). 
          
12. Retreatment This outcome refers to the need for a person to have repeat treatment of the same procedure, usually 
because of persistence of disease either on repeat biopsy or radiological imaging. 
          
Applicable to surgery  
13. Positive surgical margin This outcome indicates that the pathological assessment of the prostate gland after surgical removal (i.e. 
radical prostatectomy) has shown cancer at the edges of the prostate specimen. This implies that there 
may be some cancer left behind, although this is unproven, and its actual impact on long-term outcomes 
(e.g. survival) is uncertain. 
          
Other (please specify)            
 
B. Bowel Function  
  Not 
important 
Important  Critical   
Outcome Lay description 1 2 3 4 5 6 7 8 9 Unable 
to score 
14. Diarrhoea  Watery stools           
15. Faecal incontinence  Uncontrolled leakage of stools           
16. Faecal urgency Having to rush to get to the toilet to open bowels           
17. Rectal bleeding Bleeding from the back passage           
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18. Rectal itch Itching inside the back passage           
19. Constipation  Difficulty in opening bowels           
20. Bowel frequency  Having to go to the toilet more frequently than previously           
21. Painful bowel 
movements 
Pain in the back passage during defecation.           
Other (please specify)            
 
C. Urinary Function  
  Not 
important 
Important  Critical   
Outcome Lay description 1 2 3 4 5 6 7 8 9 Unable 
to 
score 
22. Urge incontinence  Uncontrolled leakage of urine associated with a sensation of having to rush to get to a toilet to urinate           
23. Stress incontinence  Uncontrolled leakage of urine associated with coughing, sneezing, running, exercising, etc.            
24. Weak urine stream  Having a very poor or intermittent urinary stream           
25. Nocturia  Having to get up during the night to urinate            
26. Haematuria Visible blood in the urine           
27. Dysuria Pain when urinating           
28. Frequency Needing to pass urine more frequently           
29. Urgency Feeling the sensation for having to rush to get to a toilet to urinate           
30. Need for a temporary 
urethral catheter 
Most patients who have surgery for prostate cancer receive a urethral catheter temporarily ranging from 
a day to 2 weeks depending on the nature of the surgical treatment. This question relates to the need for 
a catheter as part of the surgical procedure. 
          
31. Catheter-related 
problems 
These refer to problems such as catheter blocking off, leaking, bladder spasms, discomfort during 
catheter removal, etc. 
          
Other (please specify)            
 
D. Sexual Function  
  Not 
important 
Important  Critical   
Outcome Lay description 1 2 3 4 5 6 7 8 9 Unable 
to score 
32. Erectile dysfunction  Inability to have erections sufficient for penetrative intercourse, or the quality of erections being poorer           
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following treatment. 
33. Reduced or loss of 
libido 
Reduced or loss of interest in having sex           
34. Frequency of 
intercourse 
Amount of times being able to have sex            
35. Ejaculatory function Problems with ejaculation following treatment (e.g. unable to ejaculate, painful, blood in semen, dry 
ejaculate, reduced semen amount, etc.) 
          
36. Orgasmic function Problems with achieving orgasm or climax during sex.           
37. Sexual function General term referring to combination of functions, including libido, erectile function, ejaculatory function 
and orgasmic function.  
          
Other (please specify)            
 
E. Operation-specific and hospital-stay outcomes  
  Not 
important 
Important  Critical   
Outcome Lay description  1 2 3 4 5 6 7 8 9 Unable 
to 
score 
Applicable to all treatments apart from active surveillance 
38. Duration of the 
procedure  
This outcome is relevant to a person who has had surgery (including radical prostatectomy, cryotherapy 
or HIFU) only. It refers to how long it takes to complete the procedure.  
          
39. Pain  This outcome is relevant to people who have had any interventions. It refers to pain experienced during 
and immediately after the intervention.  
          
40. Use of pain relief 
medications after 
procedure   
This outcome refers to the amount of medication for pain relief patients need after their intervention           
41. Catheter duration  This outcome refers to the length of time a urethral catheter is left in after a procedure           
42. Duration of hospital 
stay 
This outcome is only relevant to an individual who has a procedure requiring them to stay in hospital. It 
refers to the length of time spent in hospital during and after the treatment.  
          
43. Time to full recovery This refers to the length of time it takes for a person to return to their normal level of activities and 
functioning (i.e. day-to-day life) after their intervention is completed.  This includes things like being 
able to drive, going to work, and being involved in leisure activities and hobbies (e.g. playing golf, 
walking, gardening, etc.).  
          
44. Time to partial 
recovery 
This refers to the length of time it takes for a person to achieve a partial return to their normal level of 
activities and functioning (i.e. day-to-day life) after their intervention is completed.  For example, being 
able to walk only with assistance, being able to drink fluids but not tolerate solid diet, being able to walk 
but not climb stairs, etc.  
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Applicable to radical prostatectomy only 
45. Blood loss This outcome is relevant to a person who has had radical prostatectomy only. It refers to the volume of 
blood lost during a surgical intervention for prostate cancer.  
          
Other (please specify)            
 
F. Quality of life and Emotional well-being 
  Not 
important 
Important  Critical   
Outcome Lay description  1 2 3 4 5 6 7 8 9 Unable 
to score 
46. Anxiety Feeling anxious either during or after treatment.           
47. Depression  Feeling depressed either during or after treatment.            
48. Lack of confidence Feeling less confident about life in general (e.g. in going out, socialising, etc.).           
49. Feeling less masculine  Feeling less masculine as a result of treatment.           
50. Feeling tired or 
fatigued 
Feeling tired, fatigued or lethargic either during or after treatment.           
51. Overall quality of life Quality of life in general related to physical and emotional wellbeing.           
52. Quality of life relating 
to urinary function 
Quality of life specifically related to urinary function.           
53. Quality of life relating 
to sexual function 
Quality of life specifically related to sexual function.           
54. Quality of life relating 
to bowel function 
Quality of life specifically related to bowel function.           
55. Quality of life impact 
on immediate family 
Impact of treatment on immediate family members in terms of their quality of life.           
Other (please specify)            
 
G. Adverse events (unwanted side effects) during and after Hormone Therapy  
  Not 
important 
Important  Critical   
Outcome Lay description 1 2 3 4 5 6 7 8 9 Unable 
to score 
56. Hot flushes Sudden feeling of warmness, usually experienced most intensely over the face, neck and chest, and may 
be associated with redness over the skin and sweating.  
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57. Swelling of the breast 
tissue (gynaecomastia) 
Generalised swelling or enlargement of the breasts due to hormonal changes.           
58. Loss of libido  Loss of interest in, and desire for, sexual activity.           
59. Erectile dysfunction Inability to have erections sufficient for penetrative intercourse, or the quality of erections being poorer 
following treatment. 
          
60. Body fat gain General body fat gain           
61. Fatigue  Extreme tiredness or lethargy.           
Other (please specify)            
 
H. Adverse events (unwanted side effects) during and after radiation therapy (including External Beam Radiotherapy and Brachytherapy)   
  Not 
important 
Important  Critical   
Outcome Lay description 1 2 3 4 5 6 7 8 9 Unable 
to 
score 
62. Anal discomfort  Discomfort in the back passage.           
63. Urethral stricture Blockage to the water passage within the penis due to formation of scar tissue.           
64. Radiation proctitis Inflammation of the rectum caused by radiotherapy           
65. Acute urinary 
retention 
Inability to pass water, sometimes resulting in painful swelling of the bladder.           
66. Fatigue  Feeling tired or lethargic.           
67. Haematuria Passing blood mixed with urine.           
Other (please specify)            
 
I. Adverse events for surgery (including open, laparoscopic and robotic surgery, cryotherapy and HIFU 
  Not 
important 
Important  Critical   
Outcome Lay description 1 2 3 4 5 6 7 8 9 Unable 
to score 
68. Acute or sub-acute 
bowel obstruction 
Sudden blockage to the gut due to formation of scar tissue within the gut or surrounding areas.           
69. Acute urinary 
retention 
Inability to pass water resulting in painful swelling of the bladder.           
70. Anastomotic leak  Leakage of urine as a result of the joint between the bladder and water pipe not being watertight.           
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71. Blood transfusion Need for blood being replaced due to excessive blood loss.            
72.Wound problems Opening of abdominal or pelvic wound due to the wound breaking down, or wound infection.           
73. Bowel injury Accidental damage to the gut.           
74. Nerve damage or 
neuropraxia 
Accidental damage or pressure on the obturator nerve during surgery which causes temporary weakness 
of the legs. 
          
75. Perioperative deaths Death occurring either during surgery or in the first week following surgery.           
76. Prolonged indwelling 
catheter 
Prolonged need for a urethral catheter following surgery.           
77. Thromboembolic 
disease 
Blood clot in the blood vessels draining blood from the legs (DVT), or vessels supplying blood to the lungs 
(pulmonary embolism). 
          
78. Rectourethral fistula Development of an abnormal channel which creates a connection between the rectum and water pipe, 
usually due to damage to the rectum occurring during surgery. 
          
79. Urethral or 
anastomotic stricture 
Narrowing of the water pipe or bladder neck area due to scar tissue causing blockage.           
Other (please specify)            
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Appendix 2: Detailed Characteristics of HCPs completing all 3 Delphi survey rounds  
Name City, country of residence  Expertise  
Alan Mcneill Edinburgh, Scotland (UK) Surgery (lap) 
Alasdair Innes Edinburgh, Scotland (UK) Urology CNS 
Alessandro Volpe Novara, Italy Surgery (robotic) 
Axel Bex Amsterdam, The Netherlands Surgery (robotic) 
Axel Merseburger Hannover, Germany Surgery 
Balazs Binnyei Aberdeen, Scotland (UK) Oncology (medical) 
Borje Ljungberg Umea, Sweden Surgery 
Brian Corr Inverness, Scotland (UK) Urology CNS 
Danny Lynch Aberdeen, Scotland (UK) Oncology CNS 
David Douglas Inverness, Scotland (UK) Surgery (lap/robotic) 
David Vrana Aberdeen, Scotland (UK) Oncology (medical) 
Debbie Munro Aberdeen, Scotland (UK) Urology CNS 
Duncan McLaren Newcastle, England (UK) Oncology (clinical) 
Eric Borg Aberdeen, Scotland (UK) Urology CNS 
Graham Macdonald Aberdeen, Scotland (UK) Oncology (clinical) 
Grant Stewart Edinburgh, Scotland (UK) Surgery (lap) 
Hashim Ahmed London, England (UK) Surgery (HIFU) 
Henk Van der Poel Amsterdam, The Netherlands Surgery (robotic) 
Hugh Mostafid Basingstoke, England (UK) Surgery (lap) 
Ian Pearce Manchester, England (UK) Surgery (lap) 
James N’Dow Aberdeen, Scotland (UK) Surgery 
Jim Catto Sheffield, England (UK) Surgery (robotic) 
Judith Grant Aberdeen, Scotland (UK) Oncology (clinical) 
Justine Royle Aberdeen, Scotland (UK) Surgery (lap/robotic) 
Kevin Wardlaw Aberdeen, Scotland (UK) Urology CNS 
Lesley Simpson Aberdeen, Scotland (UK) Urology CNS 
Linda Pennet Aberdeen, Scotland (UK) Urology CNS 
Malcolm Mason  Cardiff, Wales (UK) Oncology (clinical) 
Nicholas Cohen Aberdeen, Scotland (UK) Surgery 
Nicolas Mottet St. Etienne, France Surgery (lap) 
Pam Barker Aberdeen, Scotland (UK) Surgery 
Paul Abel  London, England (UK) Surgery 
Paul Halliday Dundee, Scotland (UK) Surgery 
Peter Cooke Wolverhampton, England (UK) Surgery 
Philip Cornford Liverpool, England (UK) Surgery (robotic) 
Philipp Dahm Minneapolis, USA Surgery 
Rakesh Heer Newcastle, England (UK) Surgery 
Robert Jones Glasgow, Scotland (UK) Oncology (medical) 
Robert Mills Norwich, England (UK) Surgery 
Roger Kocklebergh Leicester, England (UK) Surgery  
Sam McClinton Aberdeen, Scotland (UK) Surgery 
Satchi Swami Aberdeen, Scotland (UK) Surgery  
Page 38 of 40BJU International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
Steve Leung Dunfermline, Scotland (UK) Surgery 
Steven Canfield  Houston, USA Surgery (robotic) 
Thomas Lam  Aberdeen, Scotland (UK) Surgery (lap/robotic) 
Thomas Wiegel Ulm, Germany  Oncology (clinical) 
William Cross Leeds, England (UK) Surgery (robotic) 
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Appendix 3: Results of voting for all outcomes voted on during consensus group meeting  
Outcome (applicable interventions) 
Not 
important   
Important  Critical  
A.CANCER SPECIFIC AND SURVIVAL OUTCOMES 
1. Death from any cause (universal)  5% 0% 95% 
2. Death from prostate cancer (universal) 0% 5% 95% 
3. Death from causes other than prostate cancer (universal) ++ 5% 0% 95% 
4. Local disease recurrence (universal) 0% 19% 81% 
5. Distant disease recurrence/metastases (universal) 0% 5% 95% 
6. Disease progression (universal) 0% 5% 95% 
7. Need for further treatment to augment primary treatment 
(universal) 
14% 57% 29% 
8. Need for salvage therapy (universal) 0% 10% 91% 
9. Disease reclassification (Active surveillance)  0% 33% 67% 
10. Need for curative treatment (Active surveillance) 0% 14% 86% 
11. Treatment failure (Ablative)  0% 5% 95% 
12. Retreatment (Ablative)  10% 29% 62% 
13. Positive surgical margin (Surgery)  0% 24% 76% 
B. BOWEL FUNCTION 
14. Bowel function (universal)* 0% 20% 80% 
15. Faecal incontinence (universal) 0% 14% 86% 
C. URINARY FUNCTION 
23. Stress incontinence (universal) 14% 14% 71% 
24. Urinary Function (universal)* 0% 5% 95% 
26. Haematuria (universal) 15% 70% 15% 
30. Need for temporary catheter (universal) 40% 60% 0% 
31. Catheter-related problems (urinary function)  30% 60% 10% 
D. SEXUAL FUNCTION 
37. Sexual Function (universal)* 0% 10% 85% 
E. OPERATION SPECIFIC AND HOSPITAL-STAY OUTCOMES 
Applicable to all treatments apart from Active surveillance 
43. Time to full recovery (universal) 14% 67% 19% 
F. QUALITY OF LIFE AND EMOTIONAL WELL-BEING 
51. Overall Quality of Life (universal) 5% 10% 86% 
52. Quality of life relating to urinary function (universal) 100% 0% 0% 
54. Quality of life relating to bowel function (universal) 95% 5% 0% 
H. ADVERSE EVENTS DURING AND AFTER RADIATION THERAPY 
63. Bothersome or symptomatic Urethral stricture 0% 24% 76% 
65. Acute urinary retention (all interventions) 10% 48% 43% 
66. Fatigue (all interventions) (REWORDED) 0% 35% 65% 
68. Acute or sub-acute bowel obstruction (AE surgery)  0% 38% 62% 
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69. Acute urinary retentionall treatments 100% 0% 0% 
I. ADVERSE EVENTS DURING AND AFTER SURGERY 
70. Anastomotic leak 5% 76% 19% 
72. Wound problems 29% 62% 10% 
74. Nerve damage or neuropraxia  38% 24% 0% 
75. Perioperative deaths  5% 5% 91% 
77. Thromboembolic disease  0% 29% 71% 
79. Bothersome or symptomatic urethral or anastomotic stricture  0% 33% 67% 
Additional outcomes suggested by participants in Round 1 of Delphi 
80. Impact on relationship with partner  0% 80% 20% 
83. Induction of new cancers §    10% 24% 76% 
84. Side effects of hormonal therapy  0% 5% 95% 
85. ‘Bowel injury' and 'rectourethral fistula' considered together* 5% 47% 47% 
Key: Green cells indicate outcomes meeting consensus ‘in’. Red cells indicate ≥70% critical 
++ Although initially voted ‘in’, ‘death from causes other than prostate cancer’ was subsequently 
discussed and voted out because it is structurally related to ‘death from any cause’ and ‘death from 
prostate cancer’.  
§ Although initially voted ‘in’, ‘Induction of new cancers’ was subsequently discussed and voted out 
because it was considered to be very rare and late occurring and therefore unlikely to be feasible to 
collect in effectiveness trials. 
*Outcomes re-categorised during consensus meeting 
‘Bowel function’ includes: diarrhoea, faecal urgency, rectal bleeding, rectal itch, constipation, bowel 
frequency, and painful bowel movements 
‘Urinary function’ includes: urge incontinence, weak urine stream, nocturia, haematuria, dysuria, 
frequency, urgency, need for temporary catheter, and catheter related problems 
‘Sexual function’ includes: erectile dysfunction, reduced or loss of libido, frequency of intercourse, 
ejaculatory function, orgasmic function, and sexual function 
‘Overall quality of life’ includes: anxiety, depression, lack of confidence, feeling less masculine, 
feeling tired or fatigued, overall quality of life, quality of life relating to urinary function, quality of 
life relating to sexual function, quality of life relating to bowel function and quality of life impact on 
immediate family 
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